Recently, China's NMPA released information that Amgen’s Apremilast Tablet was approved for listing.

Apremilast Tablet is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor that is specific for cyclic adenosine monophosphate (cAMP). Inhibition of PDE4 leads to an increase in intracellular cAMP levels. The specific mechanism by which Apmilast exerts its therapeutic effects is not yet clear.

The original research drug, OTEZLA® (apremilast) tablets, was first approved in the United States in 2014, and currently approved for 3 indications in the United States:

1) Psoriatic arthritis, suitable for the treatment of adult patients with active psoriatic arthritis.

2) Psoriasis, suitable for the treatment of adult patients with moderate to severe plaque psoriasis suitable for phototherapy or systemic treatment.

3) Oral ulcers related to Behcet's disease, suitable for the treatment of adult patients with oral ulcers related to Behcet's disease.

At present, Apremilast Tablet attracts many Chinese pharmaceutical companies to imitate. Other listed companies include: Guilin Pharmaceutical, China Resources Double Crane, Zhu Yangxin Pharmaceutical, Zhengda Qingjiang, Zhaoke Pharmaceutical, Qilu Pharmaceutical, Simcere Pharmaceutical, CSPC Ouyi, etc. Wait.